
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.

Date of Report: July 16, 2015
(Date of earliest event reported)

Oragenics, Inc.
(Exact name of registrant as specified in its charter)

FL
(State or other jurisdiction
of incorporation)

001-32188
(Commission
File Number)

59-3410522
(IRS Employer
Identification Number)

4902 Eisenhower Boulevard, Suite 125
Tampa, FL
(Address of principal executive offices)

33634
(Zip Code)

813-286-7900
(Registrant's telephone number, including area code)

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

- (a) The 2015 annual meeting of shareholders of Oragenics, Inc. was held on July 16, 2015.
- (b) At the annual meeting, the following proposals were voted on by our shareholders:

PROPOSAL I: Election of Directors.

Dr. Frederick Telling, Ms. Christine Koski, Mr. Robert Koski, Mr. Charles Pope, and Dr. Alan Dunton were each re-elected as Directors, to serve until the our next annual meeting of shareholders or until their respective successors are elected and qualified or until their earlier resignation, removal from office or death. The votes were as follows:

	For	Withheld	Broker Non-Votes
Dr. Frederick Telling	24,374,527	2,074,276	5,805,776
Christine Koski	25,822,258	626,545	5,805,776
Robert Koski	25,824,618	624,185	5,805,776
Charles Pope	23,985,409	2,463,394	5,805,776
Dr. Alan Dunton	24,063,150	2,385,653	5,805,776

PROPOSAL II: To conduct a non-binding advisory vote on executive compensation. The votes were as follows:

FOR	26,117,066
AGAINST	264,025
ABSTAIN	67,712
BROKER NON-VOTES	5,805,776

PROPOSAL III: Ratification of the selection of Mayer Hoffman McCann P.C. as the Company's independent auditors for the year ending December 31, 2015.

FOR	32,215,650
AGAINST	34,824
ABSTAIN	4,105

Item 8.01 Other Events.

On July 17, 2015 Oragenics, Inc. (the "Company") issued a press release announcing that the Board of Directors had been re-elected.

A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated July 17, 2015

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 21st day of July, 2015.

ORAGENICS, INC.
(Registrant)

BY: /s/ Michael Sullivan

Michael Sullivan
Chief Financial Officer



Oragenics Shareholders Re-elect Existing Board of Directors; Approve and Ratify other Proposals

For Immediate Release

TAMPA, FL – July 17, 2015 – Florida-based biopharmaceutical company Oragenics, Inc. (NYSE:MKT – OGEN) has announced today that, based on proxies submitted to the independent Inspector of Election for its 2015 Annual Meeting of Shareholders, results indicate that Oragenics shareholders have re-elected the existing Board of Directors comprised of Dr. Frederick W. Telling, Christine L. Koski, Robert C. Koski, Charles L. Pope, and Dr. Alan Dunton.

“We are pleased with the outcome of the vote and especially appreciate the strong expressions of support from so many of our shareholders for our strategic transformation and the continued execution of our plan,” said Dr. Frederick Telling Oragenics Chair. “Our Board and management value the open dialogue and input we have received from our shareholders, and we look forward to continuing to execute our strategic vision.”

Additionally the shareholders also approved the advisory note of executive compensation as well as the ratification of the selection of Mayer Hoffman McCann P.C as the Company’s independent auditor.

A tabulation of the votes on these matters will be included in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission.

Dr. Telling was re-elected as Chairman of the Board of Directors at the statutory meeting of the Board held directly after the Annual General Meeting.

The Board of Directors also designated on behalf of the Company Michael Sullivan, the Company’s Chief Financial Officer and Interim Principal Executive Officer, as an “executive officer” of the Company and an officer for purposes of Section 16 of the Exchange Act of 1934 (the “Exchange Act”), and as the only officer of the Company who is subject to Section 16 of the Exchange Act and the only executive officer of the Company as that term is defined under Rule 3b-7 under the Exchange Act.

About Oragenics, Inc.

Oragenics, Inc. is focused on becoming the world leader in novel antibiotics against infectious disease and probiotics for oral health in humans and pets. Oragenics, Inc. has previously established two exclusive worldwide channel collaborations with Intrexon Corporation Inc. (XON), a synthetic biology company. The collaborations will allow Oragenics access to Intrexon’s proprietary technologies with the idea of accelerating the development of much needed new antibiotics that will work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases. Oragenics also develops, markets and sells proprietary OTC probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora both in the United States and through the use of distributors in locations outside of the United States.

For more information about Oragenics, visit www.oragenics.com. Follow Oragenics on [Facebook](#) and [Twitter](#).

Safe Harbor Statement: *Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in the filings of Oragenics with the U.S. Securities and Exchange Commission. There is no guarantee that any of the events anticipated by these forward looking statement will occur. If any of the events occur, there is no guarantee what effect they will have on company operations or financial condition. Any responsibility to update forward-looking statements is expressly disclaimed.*

Orogenics Corporate Contact**Michael Sullivan**

Chief Financial Officer

Orogenics, Inc.

4902 Eisenhower Drive, Suite 125

Tampa, FL 33634

Tel: 813-286-7900

msullivan@orogenics.com**Investor / Media Contacts****David Burke**

The Ruth Group

Tel: 646-536-7009

dburke@theruthgroup.com